Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

XERS

+ Watchlist+ Portfolio

Xeris Biopharma Holdings, Inc.

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$16.80
52-Week Range
$5.25 – $17.28
Market Cap
$3.10B
P/E (TTM)
—
EPS (TTM)
-0.03
Dividend Yield
0.00%
Advanced Metrics
Price/Book
63.63
PEG Ratio
—
Return on Equity
-27.11%
Return on Assets
7.37%
Gross Margin
87.38%
Operating Margin
12.70%
Profit Margin
-1.76%
Current Ratio
2.15
Debt/Equity
4.63
Total Debt
$226.07M
Free Cash Flow
$51.11M
Revenue Growth
44.20%
Earnings Growth
1616.20%
Enterprise Value
$3.20B

Market Snapshot

About

Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company leveraging its formulation science expertise to develop and commercialize ready-to-use injectable and infusible drug formulations. The company's marketed products include Gvoke (glucagon injection) for severe hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for Cushing's syndrome. Xeris focuses on improving patient outcomes through innovative drug delivery solutions.